We are pleased to announce that our SHS Capital portfolio company CoreMedic has announced the successful first-in-human transcatheter application of its ChordArt Mitral Valve Vision Repair System.<\/p>\n
The patient, who suffered from severe degenerative mitral regurgitation due to a mitral valve leaflet, was successfully treated with the ChordArt TMVr system as part of CoreMedic’s first-in-human trial of percutaneous replacement of the mitral chordae tendineae. This has the potential to fundamentally change the treatment of primary mitral regurgitation, a serious condition that affects millions of people around the world.<\/p>\n
Josef Bogensch\u00fctz, the new CEO of CoreMedic GmbH, said: “We are thrilled to have reached this historic milestone with our revolutionary ChordArt TMVr system, a novel approach to percutaneous mitral valve repair. We would like to thank everyone who played a key role in making this success a reality. This achievement is a testament to the dedication and hard work of our exceptional team, and we are very grateful for their contributions. With our state-of-the-art solution, we are able to position ourselves as the market leader in catheter-based mitral valve repair. We are committed to redefining the gold standard and setting new benchmarks for excellence in the future.”<\/p>\n